Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merrimack Halts Lung Cancer Trial; Stock Plunges More Than 32 Percent

Merrimack Pharmaceuticals’ stock plunged more than 32 percent after the company announced the termination of the SHERLOC Phase II clinical trial.

Read More »

Proteostasis Therapeutics’ Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance

Boston-based Proteostasis Therapeutics announced positive preliminary data from the ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis. Despite being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading hands.

Read More »

Kidney cancer combo meets main study goals

Merck & Co.’s cancer drug Keytruda in combination with Pfizer Inc.’s Inlyta met the main goals of a late-stage study for the most common form of kidney cancer.

Read More »

Eisai and Purdue’s Lemborexant Positive in Phase III Trial for Insomnia

Eisai Co. and Purdue Pharma L.P. announced top-line results from the companies’ SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.

Read More »

Restless legs syndrome linked with risk for suicidal thoughts

People with restless legs syndrome may be more likely to think about suicide or to actually make plans to take their own lives, compared to people without the condition, a new study suggests.

Read More »

Late-stage Dupixent trials show positive results

Drugmakers Sanofi and Regeneron received positive results for Dupixent, which treats eczema and is seen as a key driver of future revenues.

Read More »

Opdivo fails to meet lung cancer study goal

Bristol-Myers Squibb’s blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.

Read More »

Bristol-Myers to invest in Compugen, collaborate in clinical trials

Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.

Read More »

Novartis’ Crizanlizumab Frees Patients From Sickle Cell Pain Crises, Post Hoc Analysis Shows

A post-hoc analysis of a Phase II sickle cell disease study showed that patients treated with Novartis’ experimental humanized anti-P-selectin monoclonal antibody crizanlizumab significantly reduced occurrences of vaso-occlusive crisis, a serious disease complication that can lead to organ failure.

Read More »

Roche and Novartis Strengthen Their Presence in the MS Market

Roche company Genentech has released data from a long-term clinical trial of Ocrevus (ocrelizumab) in multiple sclerosis. The U.S. FDA and the European Medicines Agency accepted Novartis’ marketing applications for siponimod (BAF312) to treat secondary-progressive multiple sclerosis in adults.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom